Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brexpiprazole once-weekly oral formulation PK and safety in schizophrenia
jRCT2080224899Phase 1Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of brexpiprazole in schizophrenia, sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoints: Pharmacokinetic parameters of brexpiprazole once-weekly vs conventional tablet and Steady-state achievement of brexpiprazole once-weekly 48 mg formulation. Started Oct 2019; status: completed.
02
Drugs
brexpiprazole
03
Conditions
schizophrenia
Beyond the preview
Go deeper on jRCT2080224899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224899.